Tickerover
Healthcare

AMPH Stock Analysis

Amphastar Pharmaceuticals, Inc. · current price $22.01 (+0.59% today)

Setup looks favourable on the available data. Momentum, fundamentals and macro indicators are aligned.
★★★★
Quality
📊

The six-pillar scorecard

Momentum
72
Trending up strong
price trend
Growth
25
Barely growing
sales & profit growth
Quality
89
High quality
profitability & balance sheet
Valuation
60
Fairly priced
is the price fair?
Sentiment
30
Out of favour
analyst & crowd mood
Risk
59
Moderate risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
1-month momentum1-month momentum: 7575RSI zoneRSI zone: 100100GrowthGrowth: 5050FundamentalsFundamentals: 9191Trend strengthTrend strength: 6565Earnings accelerationEarnings acceleration: 100100Relative strengthRelative strength: 4545
Margin profileWhat survives each step down the income statement.
GrossGross: 47.7%47.7%OperatingOperating: 21.6%21.6%NetNet: 10.8%10.8%Free cash flowFree cash flow: 20.9%20.9%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +48.3% vs estimate+48%2026-062026-03: -40.5% vs estimate-40%2026-032025-12: -20.5% vs estimate-20%2025-122025-09: +12.7% vs estimate+13%2025-09
👁

Hype Check

Reading AMPH’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading AMPH’s filings…

📣

Latest earnings

LAST EARNINGS Amphastar Pharmaceuticals, Inc. (AMPH)

Latest earnings

EPS
$0.93 vs $0.83 est · +12.7% vs estimate BEAT
Revenue
$183.9M · -4.1% YoY
Stock reaction (1M)
+8.0%
Beat streak
2 of last 4 quarters
💰

Valuation

P/E
13.0×
Forward P/E
6.9×
Price / Sales
1.3×
Price / Book
1.2×
EV / EBITDA
6.9×
Analyst target
$22.50
Target range
$20.00 – $30.00
Implied upside
+2.2%
🩺

Financial health

Gross margin
47.7%
Operating margin
21.6%
Net margin
10.8%
FCF margin
20.9%
Return on equity
10.3%
Debt / equity
0.90
Revenue growth YoY
+5.4%
EPS growth YoY
+4.7%
📈

Technicals

$16.6552-week range$31.26
RSI (14)
64
50-day MA
$20.21
200-day MA
$22.60
ATR (14)
0.65
Beta
0.90
1-month return
+8.0%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.93$0.83+12.7%Beat
2025-12-31$0.73$0.92-20.5%Miss
2026-03-31$0.42$0.71-40.5%Miss
2026-06-30$0.91$0.61+48.3%Beat
Beat 2 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.28%
Beta
0.90
📰

Latest news on AMPH

🔗

Similar stocks in Healthcare

Frequently asked

What is AMPH's Quant Score?

Amphastar Pharmaceuticals, Inc. (AMPH) currently has a TickerMover Quant Score of 61/100, rated ★★★★ Quality. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Amphastar Pharmaceuticals, Inc. (AMPH) a buy?

TickerMover does not give buy or sell recommendations. AMPH scores 61/100 (★★★★ Quality) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is AMPH's score updated?

AMPH's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for AMPH →